DAVID A LOWE
Electrician in Boston, MA
License number
Massachusetts 37874
Issued Date
Dec 27, 1995
Expiration Date
Jul 31, 2019
Type
Journeyman Electrician
Address
Address
Boston, MA 02118
Personal information
See more information about DAVID A LOWE at radaris.comName
Address
Phone
4 Kingswood Dr APT B2, Abington, MA 02351
42 Tavern Cir, Sudbury, MA 01776
51 Exchange St, Milford, MA 01757
Organization information
See more information about DAVID A LOWE at bizstanding.comBoston Children's Hospital - David Lowe MD
300 Longwood Ave #FEGAN10, Boston, MA 02115
Categories:
Physicians & Surgeons
Site:
Phone:
(617) 355-6000 (Phone)
Products:
Cardiology
David Lowe BS,MBBS,MD
300 Longwood Ave, Boston, MA 02115
Industry:
Pediatrician
Phone:
(617) 355-6624 (Phone)
David Alexander Lowe
Professional information
See more information about DAVID A LOWE at trustoria.com
Author (In Progress); Past Program Director; International And Local Community Conservation And Engagement Leader
Author (In Progress); Past Program Director; International And Local Community Conservation And Engagement Leader
Position:
Author (in progress): Energy Primer at Lowe Energy Education, Board Member; former Chair at Climate Action Brookline (CAB; formerly CCAB), Town Meeting Member at Brookline Town community, Board Member at Massachusetts Climate Action Network (MCAN), Founding Member at Landcare International Steering Committee
Location:
Greater Boston Area
Industry:
Renewables & Environment
Work:
Lowe Energy Education
- Brookline, MA since May 2011
-
Author (in progress): Energy Primer
Climate Action Brookline (CAB; formerly CCAB)
- Brookline, MA since 2011
-
Board Member; former Chair
Brookline Town community
- Brookline, MA since 2010
-
Town Meeting Member
Massachusetts Climate Action Network (MCAN)
- 70 communities across the Commonwealth of Massachusetts since 2007
-
Board Member
Landcare International Steering Committee
- Nairobi-based network that spans five continents since 2004
-
Founding Member
Energy Points Inc.
2011 - 2012
-
Early collaborator; Education Sector Outreach
Climate Change Action Brookline
- Brookline, MA 2007 - 2010
-
Former Chair & Co-Chair
Landcare International
2004 - 2010
-
Steering Committee Member
Climate Change Action Brookline
2007 - 2009
-
Leader
EcoLogic Development Fund
2004 - 2006
-
Consultant - program & proposal development
Earthwatch Institute
1996 - 2004
-
Program Director for Life Sciences
Boston Area Returned Peace Corps Association
1997 - 2002
-
Board Member
Stony Brook University/Institute for Conservation of Tropical Environments
1995 - 1996
-
Program Officer
US Congress, Office of Technology Assessment
1993 - 1995
-
Contractor, Researcher & Writer, Study contributor
USAID
1992 - 1993
-
Contractor, Energy and Infrastructure
National Museums of Kenya
1989 - 1991
-
Research Associate; Program Director
US Peace Corps
1984 - 1985
-
Campus Recruiter, Cornell University
Peace Corps/Kenya
1978 - 1981
-
Volunteer
Education:
Cornell University 1983 - 1986
Masters, International Agriculture and Rural Development State University of New York at Stony Brook 1973 - 1977
BS, Earth and Space Sciences JFK HS
Masters, International Agriculture and Rural Development State University of New York at Stony Brook 1973 - 1977
BS, Earth and Space Sciences JFK HS
Skills:
Energy Efficiency, Sustainability, Environmental Policy, Sustainable Development, Non-profits, Environmental Awareness, Renewable Energy, Environmental Education, Energy, Climate Change, Community Development, Green, Government Administration, Public Policy, Grant Writing, International Development, Fundraising, Program Development, Grants, Policy Analysis, Research, Strategy, Proposal Writing, Science, Conservation Issues, Nonprofits, Community Engagement, Leadership
Transgenic Flies Expressing Abeta42-Arctic
Transgenic Flies Expressing Abeta42-Arctic
US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969893
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000
Abstract:
The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Flemish
Transgenic Flies Expressing Abeta42-Flemish
US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969895
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Iowa
Transgenic Flies Expressing Abeta42-Iowa
US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969894
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Dutch
Transgenic Flies Expressing Abeta42-Dutch
US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969898
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Flemish
Transgenic Flies Expressing Abeta42-Flemish
US Patent:
2004024, Dec 2, 2004
Filed:
May 25, 2004
Appl. No.:
10/852892
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Assignee:
EnVivo Pharmaceuticals, Inc.
International Classification:
A01K067/033
US Classification:
800/003000, 800/008000
Abstract:
The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human A42 peptide of human amyloid- precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A42peptide of human amyloid- precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Italian
Transgenic Flies Expressing Abeta42-Italian
US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/970189
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Italian mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Dutch
Transgenic Flies Expressing Abeta42-Dutch
US Patent:
2004025, Dec 9, 2004
Filed:
May 25, 2004
Appl. No.:
10/853593
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Assignee:
EnVivo Pharmaceuticals, Inc.
International Classification:
A01K067/033
US Classification:
800/008000, 800/009000
Abstract:
The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human A42 peptide of human amyloid- precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A42peptide of human amyloid- precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
Transgenic Flies Expressing Abeta42-Arctic
Transgenic Flies Expressing Abeta42-Arctic
US Patent:
2004025, Dec 16, 2004
Filed:
May 25, 2004
Appl. No.:
10/852951
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Assignee:
EnVivo Pharmaceuticals, Inc.
International Classification:
G01N033/00, A01K067/00, A01K067/033
US Classification:
800/003000, 800/013000
Abstract:
The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human A42 peptide of human amyloid- precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A42peptide of human amyloid- precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.